---
figid: PMC3542227__cbt-13-1376-g5
figlink: /pmc/articles/PMC3542227/figure/F5/
number: ''
caption: Figure 5. Working model for the role of EML4-ALK chimeric kinase in driving
  the progression of NSCLC through activation of the EGFR pathway. The EML4-ALK protein
  phosphorylates and activates Ras signaling leading to a cascade of events driving
  cellular proliferation and growth. There are multiple redundancies in this pathway
  susceptible to targeted small molecule therapy. We propose that using agents such
  as Sorafenib with good CNS penetration distal to ALK-signaling represents an opportunity
  to overcome therapeutic resistance and reduce CNS failure. EGFR, epidermal growth
  factor receptor dimer; AKT, a serine/threonine-specific protein kinase; ERK, extracellular-signal
  related kinases; IKK, IκB kinase; NFκB, nuclear transcription factor kappa B; MEK,
  mitogen-activated protein kinase; RAF, protein serine/threonine protein kinase.
  →, activates; —|, inhibits.
pmcid: PMC3542227
papertitle: Isolated central nervous system progression on Crizotinib.
reftext: Stephen G. Chun, et al. Cancer Biol Ther. 2012 Dec 1;13(14):1376-1383.
pmc_ranked_result_index: '48158'
pathway_score: 0.970951
filename: cbt-13-1376-g5.jpg
figtitle: Isolated central nervous system progression on Crizotinib
year: '2012'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3542227__cbt-13-1376-g5.html
  '@type': Dataset
  description: Figure 5. Working model for the role of EML4-ALK chimeric kinase in
    driving the progression of NSCLC through activation of the EGFR pathway. The EML4-ALK
    protein phosphorylates and activates Ras signaling leading to a cascade of events
    driving cellular proliferation and growth. There are multiple redundancies in
    this pathway susceptible to targeted small molecule therapy. We propose that using
    agents such as Sorafenib with good CNS penetration distal to ALK-signaling represents
    an opportunity to overcome therapeutic resistance and reduce CNS failure. EGFR,
    epidermal growth factor receptor dimer; AKT, a serine/threonine-specific protein
    kinase; ERK, extracellular-signal related kinases; IKK, IκB kinase; NFκB, nuclear
    transcription factor kappa B; MEK, mitogen-activated protein kinase; RAF, protein
    serine/threonine protein kinase. →, activates; —|, inhibits.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R4
  - PIK3CA
  - MAPK3
  - MAPK1
  - PIK3R5
  - AKT3
  - PIK3CB
  - EGFR
  - ALK
  - NRAS
  - MAP2K2
  - AKT1
  - AKT2
  - PIK3R6
  - CHUK
  - PIK3R3
  - RAF1
  - NFKB1
  - MAP2K1
  - IKBKG
  - ARAF
  - IKBKB
  - KRAS
  - HRAS
  - PIK3CD
  - PIK3CG
  - BRAF
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ALK
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: CHUK
  entrez: '1147'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKG
  entrez: '8517'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
